Redeye states that the report aligned with preliminary figures and showed net sales in line with est...
Redeye retains its positive view of Formpipe following a Q4 matching our forecasts.
Redeye updates its outlook for Xspray following its Q4 report, and we highlight that the recently an...
Redeye återkommer med en update efter BioArctics Q4-rapport som kom in lägre vår förväntan, vilket d...
Redeye regard Stille's Q4 report as strong as it came in slightly above our estimates in terms of bo...
Årsbokslutet för 2023 från Starbreeze skapade ett kursras på omkring 15% i aktien.
Sales growth +22%, ARR +14% y-o-y in Q4 We raise estimates on the new defence order Good outlook for...
We lower '24e and '25e adj. EBITA by 3% and 6% 5% EBITA growth in '24e driven by HQ cost cuts '24e E...
Net sales and clean EBIT were below market consensus (LSEG) in Q4 but ESL Shipping segment were slig...
In line with the already communicated ambition to divest its Gesture Interaction business, Crunchfis...
Redeye updates its estimates and fair value range following Arise’s Q4 2023 report.
Redeye reviews Medivir's fourth quarter report, which disclosed further improvements in patient surv...
Redeye provides an update in relation to Optomed’s Q4 2023 report.
NoHo Partners' Q4 2023 EBIT fell 5% short of Vara Research consensus but grew by 25% y/y, with sales...
Q4e numbers to mark a strong end to '23 with no major surprises '24e: We expect 26% ARR growth and b...
Mendus has reported FY23 results, summarising an active period.
Challenging market in Q4 EBIT estimates cut by 5-10% for 2024-25e 2024e EV/EBIT of 4x with 4-5% divi...
On February 14th, Eevia Health published the company’s quarterly report for Q4-23.
Q4 sales SEK 27.9m, up 29% y-o-y, adj. EBIT SEK -6.
1% organic sales growth y-o-y Profitability still at a good level Lower utilisation rather than drop...
